References
- Ali Z, Mishra N, Baldi A. 2016. Development and characterization of arteether-loaded nanostructured lipid carriers for the treatment of malaria. Artif Cells Nanomed Biotechnol. 44: 545–549.
- Autino B, Noris A, Russo R, Castelli F. 2012. Epidemiology of malaria in endemic areas. Mediterr J Hematol Infect Dis. 4:e2012060
- Cesar IC, Pernetti AP. 2009. Quantitation of artemether in pharmaceutical raw material and injections by high performance liquid chromatography. Braz J Pharm Sci. 4:737–742.
- Fule R, Meer T, Sav A, Amin P. 2013. Solubility and dissolution rate enhancement of lumefantrine using hot melt extrusion technology with physicochemical characterization. Int J Phar Investig. 43:305–321.
- Hanaor D, Michelazzi M, Leonelli C, Sorrell CC. 2012. The effects of carboxylic acids on the aqueous dispersion and electrophoretic deposition of ZrO2. J Eur Ceram Soc. 32:235–244.
- Laxmi M, Bhardwaj A, Mehta S, Mehta A. 2014. Development and characterization of nanoemulsion as carrier for the enhancement of bioavailability of artemether. Nanomed Biotechnol. 43:334–344.
- Malaria Fact sheet N°94. WHO. March 2014; Available from: http://www.who.int/malaria/media/world_malaria_report_2014/en/. [cited 2014 Aug 28].
- World Health Organization. 2010. Guidelines for the Treatment of Malaria (2nd ed.). Geneva: World Health Organization, p. ix.
- Margret R, Palanisamy P, Jayakar B, Pasupathi A. 2014. Formulation and evaluation of fast dissolving tablets of Artemether and Lumefantrine. J Pharm Res. 8:S1467–S1474.
- Olumide SA, Raji Y. 2011. Long-term administration of artesunate induces reproductive toxicity in male rats. J Reprod Infertil 12:249–260.
- Patel A, Lodha A, Chaudhari J, Jadia P, Joshi T, Dalal J. 2012. Formulation, process development and evaluation of artemether and lumefantrine soft gelatin capsule. J Pharm Bioallied Sci. 4:S98–S100.
- Sandhya SM, Shijikumar PS, Meena S. 2015. A sensitive liquid chromatographic assay for the simultaneous determination of lumefantrine and artemether in human plasma. Indo Am J Pharm Sci. 5:720–726.
- Shende P, Gaud RS, Deshmukh K, Cavalli R, Trotta F, Caldera F, Biasizzo M. 2012. Influence of different techniques on formulation and comparative characterization of inclusion complexes of ASA with β-cyclodextrin and inclusion complexes of ASA with PMDA cross-linked β-cyclodextrin nanosponges. J Incl Phenom Macrocycl Chem. 72:447–454.
- Shende P, Gaud RS, Deshmukh K, Cavalli R, Trotta F, Caldera F. 2013. Novel cyclodextrin nanosponges for delivery of calcium in hyperphosphatemia. Int J Pharm. 456:95–100.
- Yang B, Lin J, Chen Y, Liu Y. 2009. Artemether/hydroxypropyl-beta-cyclodextrin host-guest system: characterization, phase-solubility and inclusion mode . Bioorg Med Chem Lett. 17:6311–6317.
- WHO List of Essential Medicines, 18th list, April 2013.
- WHO Technical Report Series 937. 2006. Annex 8: Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms.